Gastrointestinal Cancer

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

The FDA has granted a priority review designation to nivolumab (Opdivo) for use as a treatment for patients with hepatocellular carcinoma following prior sorafenib (Nexavar).

The FDA has granted a priority review to a supplemental Biologics License Application for pembrolizumab (Keytruda) for the treatment of patients who have undergone at least 2 courses of chemotherapy for recurrent or advanced gastric or gastroesophageal junction adenocarcinoma.

Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Cynthia L. Sears, MD, professor of Medicine, at Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses ongoing research of microbiota for patients with colorectal cancer (CRC).

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the challenges facing the future treatment of patients with cholangiocarcinoma.

Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.

Findings of a new prospective study suggest that eating tree nuts like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer.

Treatment with adjuvant capecitabine improved overall survival by 15 months compared with observation alone for patients with macroscopically resected biliary tract cancer, according to findings from the phase III BILCAP study released in advance of the 2017 ASCO Annual Meeting.

Extensive studies into molecular aberrations in colorectal cancer are yielding fresh insights into the potential clinical utility of checkpoint immunotherapies, genetic testing, and tumor-sidedness implications. Experts weigh in on key developments that may change treatment paradigms.

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).

Tim F. Greten, MD, discussed the evolving role of immunotherapy in hepatocellular carcinoma.

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Anne Julia Klompenhouwer, MD, Department of Surgery at Erasmus Medical Center in Rotterdam, The Netherlands, discusses when it is justified to resect a larger hepatocellular adenoma for patients with hepatocellular carcinoma (HCC).

Jonathan Strosberg, MD, discusses recent developments and emerging agents in the field of neuroendocrine tumors.

Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.

Researchers have successfully performed autonomous retroflexion of a robotic capsule during colonoscopy in a subject animal, according to data presented during Digestive Disease Week 2017 at McCormick Place in Chicago.

Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.